Two substances tested together on brain tumor cells in a lab dish
Original title: All-Trans Retinoic Acid and Curcumin Exhibit Hormesis or Synergistic Anticancer Effects in U87 Glioblastoma Cells: Defining the Proteome Accompanying Synergism.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This was only tested on tumor cells in a lab dish.
The short version
Scientists tested two substances on brain tumor cells in a dish, and the dose changed what happened.
What was studied. Researchers used glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary cells grown in a lab dish. They tested a form of vitamin A called ATRA and curcumin, which comes from the spice turmeric. They tried each one alone and both together at low and high doses.
What they found. At high doses, ATRA slowed cell growth and cell movement better than curcumin. At low doses, both substances made the cells grow more, and curcumin worked against the other drug. At the highest doses, the two together slowed cell movement and helped kill tumor cells, and they also changed some proteins inside the cells.
What this means, and what it doesn't
What it could mean: This helps scientists learn how these two substances act on brain tumor cells. It also shows that a low dose may help tumor cells grow instead of stopping them. That is a good reason not to try these on your own.
What it doesn't mean: This does not mean vitamin A or curcumin can treat a brain tumor. The work was done only on cells in a dish, not in animals or people. It is very far from everyday care. It is not a cure. Please talk with your care team before taking any supplement.
Source: PubMed, August 31, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.